Breaking News, Collaborations & Alliances

Innovent Biologics & Roche Partner to Advance Development of IBI3009

Collaboration aims to bring innovative treatment options to patients with advanced small cell lung cancer.

Author Image

By: Charlie Sternberg

Associate Editor

Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a collaboration and exclusive license agreement with Roche to advance the development of IBI3009, a novel DLL3-targeted antibody drug conjugate (ADC) candidate. IBI3009 has already obtained IND approvals in Australia, China, and the U.S., with the first patient for the Phase 1 study dosed in December 2024. This collaboration aims to bring innovative treatment options to p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters